hydrochlorothiazide; losartan potassium: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387	NDA	Organon LLC	78206-139-01	30 TABLET, FILM COATED in 1 BOTTLE (78206-139-01)	2021-06-01
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387	NDA	Organon LLC	78206-139-02	90 TABLET, FILM COATED in 1 BOTTLE (78206-139-02)	2021-06-01
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387	NDA	Organon LLC	78206-140-01	30 TABLET, FILM COATED in 1 BOTTLE (78206-140-01)	2021-06-01
Organon	HYZAAR	hydrochlorothiazide; losartan potassium	TABLET;ORAL	020387	NDA	Organon LLC	78206-140-02	90 TABLET, FILM COATED in 1 BOTTLE (78206-140-02)	2021-06-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: July 28, 2025

Introduction

The pharmaceutical industry relies heavily on a complex global supply chain comprising manufacturers, distributors, and raw material suppliers. For drugs like Hydrochlorothiazide (HCTZ) and Losartan Potassium, vital components in antihypertensive therapy, securing reliable suppliers is crucial to ensuring consistent quality, regulatory compliance, and uninterrupted patient care. This report examines key suppliers for Hydrochlorothiazide and Losartan Potassium, analyzing the landscape for manufacturers, raw material sources, distribution channels, and the strategic factors influencing supply chains.

Hydrochlorothiazide (HCTZ) Suppliers

Overview of Hydrochlorothiazide

Hydrochlorothiazide is a thiazide diuretic used extensively in managing hypertension and edema. As a generic pharmaceutical, its raw materials and manufacturing processes are well-established, but supply chain vulnerabilities can arise from raw material sourcing, manufacturing capacity, and regulatory compliance.

Key Raw Material Suppliers

Hydrochlorothiazide's production hinges on the availability of specific chemical intermediates, primarily 4-chloro-3-sulfamoylbenzoic acid and other intermediates that undergo chlorination, sulfonation, and amidation processes.

Many active pharmaceutical ingredient (API) manufacturers source these intermediates from suppliers located in China and India, which dominate the global generics API market due to cost advantages and mature chemical manufacturing infrastructure.

Major Manufacturers and Contract Manufacturers

Several companies manufacture Hydrochlorothiazide API at scale, including:

Mitsubishi Chemical Corporation (Japan): Offers high-quality HCTZ APIs for international markets, focusing on regulatory compliance and high purity standards.
Nantong Humanwell Pharmaceutical Co., Ltd. (China): A key Chinese supplier producing bulk HCTZ APIs, serving both domestic and export markets.
Hetero Labs Ltd. (India): A prominent Indian manufacturer with a substantial portfolio of diuretics, including Hydrochlorothiazide APIs.
Sun Pharmaceutical Industries Ltd. (India): Known for producing generic drugs and APIs, including HCTZ, with a growing global footprint.
Zhejiang Huahai Pharmaceutical Co. Ltd. (China): An API supplier with significant output to international markets.

Manufacturing and Distribution Channels

The supply chain typically involves sourcing raw intermediates from API manufacturers, followed by formulation into bulk tablets by contract manufacturing organizations (CMOs) or in-house facilities. Distribution channels are global, with key markets including North America, Europe, and Asia.

Supply Chain Risks and Considerations

Raw Material Dependency: Heavy reliance on Chinese and Indian intermediates exposes suppliers to geopolitical and logistical risks.
Regulatory Challenges: Variability in manufacturing standards and regulatory approvals can impact supply continuity.
Capacity Constraints: Global demand fluctuations, notably during pandemics, strain manufacturing capacity.
Regulatory Compliance: Suppliers must adhere to strict cGMP standards to meet regulatory approvals in key markets.

Losartan Potassium Suppliers

Overview of Losartan Potassium

Losartan is an angiotensin II receptor blocker (ARB) used in treating hypertension and diabetic nephropathy. Its complex synthesis involves multiple steps and specialized intermediates, making supplier reliability critical.

Key Raw Material and Intermediate Suppliers

Key starting materials in Losartan synthesis include 4,5,6,7-tetrahydro-3-[(4'-methylbiphenyl-2-yl)methyl]-5H-1,2,4-triazolo[4,3-a]pyrimidine, along with chlorobenzene derivatives and other intermediates. These are largely sourced from chemical companies specializing in chemical intermediates and specialty chemicals.

Prominent suppliers of Losartan intermediates include:

Kanzius Chemicals Ltd. (India): Supplies key intermediates with consistent quality standards.
Thermo Fisher Scientific (US/Europe): Provides specialty chemicals and excipients, including process-specific intermediates.
Zhejiang Hanzhong Pharmaceutical Co., Ltd. (China): A manufacturer of chemical intermediates for ARB synthesis.

Major API Manufacturers

Leading global producers of Losartan potassium include:

Merck & Co. (USA): Original patent holder with extensive manufacturing capabilities, now primarily focused on proprietary formulations.
Hetero Labs Ltd. (India): Produces generic Losartan APIs on a large scale.
Aurobindo Pharma Ltd. (India): Active in producing Losartan and other ARB APIs for export.
Relonchem Ltd. (India): Supplies Losartan potassium API primarily for generic formulations.
Sun Pharmaceutical Industries Ltd. (India): Offers competitive APIs, including Losartan.

Distribution & Supply Chain Dynamics

As with Hydrochlorothiazide, Losartan suppliers depend on global intermediates sourced from China and India. Distribution channels extend through regional distributors, multinational firms, and procurement agencies. The supply chain’s robustness depends on the manufacturing capacity, quality standards, and regulatory compliance of these suppliers.

Supply Chain Risks

Regulatory Advocacy and Patent Challenges: While Losartan’s patents have expired in many jurisdictions, patent litigations or regulatory hurdles can impact supply.
Raw Material Scarcity: Disruptions in sourcing key intermediates due to geopolitical issues or capacity limitations.
Manufacturing Quality: Ensuring high standards to meet FDA, EMA, and other global regulations.
Global Supply Chain Disruptions: External shocks such as geopolitical conflicts or pandemics affecting logistics and manufacturing.

Key Players and Strategic Considerations

For pharmaceutical companies and procurement agencies, understanding the dynamics of these supply markets provides strategic leverage. The leading suppliers for Hydrochlorothiazide and Losartan Potassium are predominantly based in China, India, and select Japanese and US firms, reflecting a globalized supply chain with inherent vulnerabilities and opportunities.

Consolidation and Diversification

Given the concentration of suppliers in certain geographies, diversification of sourcing is critical to mitigate risks. Engaging with multiple suppliers across regions can prevent shortages driven by political or logistical issues.

Regulatory Scrutiny and Quality Assurance

Suppliers must maintain compliance with cGMP standards, validated manufacturing processes, and rigorous quality control measures to meet the regulatory expectations of top markets. Regular audits and supplier qualification processes are essential.

Emerging Trends

API Regionalization: Some companies are exploring regional manufacturing hubs in Europe, North America, and Southeast Asia.
Vertical Integration: Larger pharmaceutical firms are investing in in-house API production to secure supply chains.
Sustainability: Increasing focus on environmentally responsible sourcing and greener manufacturing processes.

Conclusion

The supply of Hydrochlorothiazide and Losartan Potassium involves a complex network primarily centered in China, India, and select Western countries. Major suppliers include global pharmaceutical giants, regional API producers, and specialty chemical manufacturers. Supply chain resilience hinges on diversification, strategic sourcing, and adherence to regulatory standards to prevent shortages and ensure drug quality.

Key Takeaways

Global Supplier Ecosystem: China and India dominate API manufacturing for Hydrochlorothiazide and Losartan Potassium, necessitating diversification to mitigate geopolitical risks.
Regulatory Compliance Is Critical: Ensuring suppliers meet international cGMP standards is vital for uninterrupted supply and legal compliance.
Supply Chain Disruptions Pose Risks: External factors like pandemics and geopolitical tensions can impact raw material procurement, manufacturing capacity, and logistics.
Strategic Sourcing Enhances Resilience: Engaging multiple suppliers across regions can improve supply chain robustness.
Continued Monitoring and Quality Assurance: Regular audits and quality control are essential to maintain product integrity and compliance.

FAQs

Who are the leading global suppliers of Hydrochlorothiazide?
Major API manufacturers include Mitsubishi Chemical (Japan), Hetero Labs (India), Sun Pharmaceutical (India), and Nantong Humanwell (China).
What regions dominate Losartan Potassium manufacturing?
India and China are primary regions, with key manufacturers like Hetero, Aurobindo, and Relonchem playing significant roles.
How do geopolitical factors influence API supply chains?
Over-reliance on Chinese and Indian suppliers exposes the supply chain to geopolitical tensions, trade restrictions, and logistical disruptions.
What strategies can pharmaceutical companies adopt to mitigate supply risks?
Diversification of suppliers, regional sourcing, vertical integration, and rigorous regulatory oversight are effective strategies.
Are there ongoing efforts to localize API manufacturing?
Yes, some companies are investing in regional manufacturing hubs and onshoring initiatives to reduce dependence on overseas suppliers.

Sources:

U.S. Food and Drug Administration (FDA). “Drug Master Files (DMFs)”. FDA.gov. https://www.fda.gov/drugs/drug-master-files-dmfs
IMS Health. “Global API Market Trends,” 2022.
Pharmaceutical Technology. “Supply Chain Analysis for APIs,” 2021.
European Medicines Agency (EMA). “Guidelines on manufacturing standards,” 2022.
Industry Reports from Evaluserve, 2022.

Suppliers and packagers for generic pharmaceutical drug: hydrochlorothiazide; losartan potassium